Takeda Pharmaceutical

Takeda Pharmaceutical TKPHF Stock

$43.05   0.000000%
Add to favorites
Market Cap
$68.77B
LOW - HIGH [24H]
$43.05 - $43.05
VOLUME [24H]
$100.00
P/E Ratio
307.50
Earnings per share
$0.14
ISIN
JP3463000004
Price   Prediction

Takeda Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

Takeda Pharmaceutical (TKPHF) stock price today is 43.05 USD on OTC Markets OTCPK (0% on the day). Updated .

Takeda Pharmaceutical TKPHF Financial and Trading Overview

Takeda Pharmaceutical stock price 43.05 USD
Previous Close 43.05 USD
Open 43.05 USD
Bid 43.15 USD x 60000
Ask 44.53 USD x 80000
Day's Range 43.05 - 43.05 USD
52 Week Range 27.63 - 43.59 USD
Volume 100 USD
Avg. Volume 9.58K USD
Market Cap 68.77B USD
Beta (5Y Monthly) 0.077
PE Ratio (TTM) 307.5
EPS (TTM) 0.14 USD
Forward Dividend & Yield 1.28 (2.97%)
Ex-Dividend Date March 31, 2027
1y Target Est N/A

TKPHF Valuation Measures

Enterprise Value 5.01T USD
Trailing P/E 307.5
Forward P/E 53.148148
PEG Ratio (5 yr expected) 0.49
Price/Sales (ttm) 0.014653041
Price/Book (mrq) 1.4665483
Enterprise Value/Revenue 1.067
Enterprise Value/EBITDA 3.666

Trading Information

Takeda Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.077
52-Week Change 55.80%
S&P500 52-Week Change 8.67%
52 Week High 43.59 USD
52 Week Low 27.63 USD
50-Day Moving Average 38.74 USD
200-Day Moving Average 35.2 USD

TKPHF Share Statistics

Avg. Volume (3 month) 9.58K USD
Avg. Daily Volume (10-Days) 40.15K USD
Shares Outstanding 1.6B
Float 1.58B
Short Ratio N/A
% Held by Insiders 1.22%
% Held by Institutions 49.00%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 202
Trailing Annual Dividend Yield 469.22%
5 Year Average Dividend Yield 438.99%
Payout Ratio 9.0502
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 0.86%
Operating Margin (ttm) 16.55%
Gross Margin 64.77%
EBITDA Margin 29.11%

Management Effectiveness

Return on Assets (ttm) 3.26%
Return on Equity (ttm) 0.56%

Income Statement

Revenue (ttm) 4.69T USD
Revenue Per Share (ttm) 2964.37 USD
Quarterly Revenue Growth (yoy) 6.70%
Gross Profit (ttm) 3.04T USD
EBITDA 1.37T USD
Net Income Avi to Common (ttm) 40.8B USD
Diluted EPS (ttm) 0.14
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 418.53B USD
Total Cash Per Share (mrq) 262 USD
Total Debt (mrq) 5.36T USD
Total Debt/Equity (mrq) 72.23 USD
Current Ratio (mrq) 1.151
Book Value Per Share (mrq) 29.354641

Cash Flow Statement

Operating Cash Flow (ttm) 879.67B USD
Levered Free Cash Flow (ttm) 681.38B USD

Profile of Takeda Pharmaceutical

Country United States
State N/A
City Chuo
Address 1-1, Nihonbashi-Honcho 2-chome
ZIP 103-8668
Phone 81 3 3278 2111
Website https://www.takeda.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 47029

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Q&A For Takeda Pharmaceutical Stock

What is a current TKPHF stock price?

Takeda Pharmaceutical TKPHF stock price today per share is 43.05 USD.

How to purchase Takeda Pharmaceutical stock?

You can buy TKPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Takeda Pharmaceutical?

The stock symbol or ticker of Takeda Pharmaceutical is TKPHF.

Which industry does the Takeda Pharmaceutical company belong to?

The Takeda Pharmaceutical industry is Drug Manufacturers - Specialty & Generic.

How many shares does Takeda Pharmaceutical have in circulation?

The max supply of Takeda Pharmaceutical shares is 1.6B.

What is Takeda Pharmaceutical Price to Earnings Ratio (PE Ratio)?

Takeda Pharmaceutical PE Ratio is 307.50000000 now.

What was Takeda Pharmaceutical earnings per share over the trailing 12 months (TTM)?

Takeda Pharmaceutical EPS is 0.14 USD over the trailing 12 months.

Which sector does the Takeda Pharmaceutical company belong to?

The Takeda Pharmaceutical sector is Healthcare.

$2.05T
Total marketcap
$79.87B
Total volume
BTC 57.68%   •   ETH 9.85%
Dominance
Select currency